Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs

GAIA BioMedicine Founder and Chief Scientific & Technology Officer Yoshikazu Yonemitsu GAIA BioMedicine, a biotech spinoff of Kyushu University, aims for regulatory filing of cancer immunotherapy using its natural killer (NK)-like cell GAIA-102 “sometime in 2025 if everything goes well,”...read more